{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T11:14:40Z","timestamp":1694258080965},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1177\/2168479016648731","type":"journal-article","created":{"date-parts":[[2016,5,22]],"date-time":"2016-05-22T22:34:40Z","timestamp":1463956480000},"page":"743-750","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Drug Use Between Clinical Practice and Regulatory Approval: Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression"],"prefix":"10.1007","volume":"50","author":[{"given":"Nanae","family":"Tanemura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Uyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Iyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,30]]},"reference":[{"key":"5006743_CR1","unstructured":"National Institute of Population and Social Security Research. Population projections for Japan (Estimate of January 2012) (summary of results) [in Japanese]. http:\/\/www.ipss.go.jp\/syoushika\/tohkei\/newest04\/gh2401.asp. Published January 30, 2012. Accessed August 29, 2015."},{"key":"5006743_CR2","unstructured":"Ministry of Health, Labour and Welfare. Studies in support of special populations: geriatrics (ICH E7) [in Japanese]. https:\/\/www.pmda.go.jp\/files\/000156302.pdf. Published February 2, 1993. Accessed August 29, 2015."},{"key":"5006743_CR3","unstructured":"Ministry of Health, Labour and Welfare. Studies in support of special populations: geriatrics (ICH E7). Questions & answers [in Japanese]. http:\/\/www.pmda.go.jp\/files\/000156457.pdf. Published September 17, 2010. Accessed August 29, 2015."},{"key":"5006743_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","volume":"57","author":"K Martin","year":"2004","unstructured":"Martin K, Begaud B, Latry P, et al. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004;57:86\u201392. doi:https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01953.x.","journal-title":"Br J Clin Pharmacol"},{"key":"5006743_CR5","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1093\/annonc\/mdq070","volume":"21","author":"K Yonemori","year":"2010","unstructured":"Yonemori K, Hirakawa A, Komiyama N, et al. Participation of elderly patients in registration trials for oncology drug applications in Japan. Ann Oncol. 2010;21:2112\u20132118. doi:https:\/\/doi.org\/10.1093\/annonc\/mdq070.","journal-title":"Ann Oncol"},{"issue":"7","key":"5006743_CR6","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11606-010-1629-x","volume":"26","author":"DM Zulman","year":"2011","unstructured":"Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011; 26(7):783\u2013790. doi:https:\/\/doi.org\/10.1007\/s11606-010-1629-x.","journal-title":"J Gen Intern Med"},{"key":"5006743_CR7","unstructured":"EFGCP Geriatric Medicines Working Party (GMWP). Medical research for and with older people in Europe. https:\/\/www.kcl.ac.uk\/sspp\/departments\/sshm\/news\/EFGCP-GMWP-Research-Guidelines-Final-edited-2013-05-27.pdf. Published May 27, 2013. Accessed October 20, 2015."},{"key":"5006743_CR8","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s12603-014-0031-5","volume":"18","author":"Y Asahina","year":"2014","unstructured":"Asahina Y, Sugano H, Sugiyama E, Uyama Y. Representation of older patients in clinical trials for drug approval in Japan. J Nutr Health Aging. 2014;18:520\u2013523. doi:https:\/\/doi.org\/10.1007\/s12603-014-0031-5.","journal-title":"J Nutr Health Aging"},{"key":"5006743_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency. Approval information of drug [in Japanese]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuSearch\/. Published April 11, 2005. Accessed August 29, 2015."},{"key":"5006743_CR10","unstructured":"Ministry of Health, Labour and Welfare. Patient survey [in Japanese]. http:\/\/www.e-stat.go.jp\/SG1\/estat\/List.do?lid=000001103073. Published November 27, 2012. Accessed August 29, 2015."},{"key":"5006743_CR11","unstructured":"Ministry of Health, Labour and Welfare. For the severity classification criteria of the adverse drug reaction, etc. [in Japanese]. http:\/\/www.mhlw.go.jp\/shingi\/2005\/10\/dl\/s1006-4f2.pdf. Published June 29, 1992. Accessed August 29, 2015."},{"key":"5006743_CR12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2710.2005.00670.x","volume":"30","author":"M Takada","year":"2005","unstructured":"Takada M, Okada H, Kotake T, et al. Appropriate dosing regimen of allopurinol in Japanese patients. J Clin Pharm Ther. 2005;30:407\u2013412. doi:https:\/\/doi.org\/10.1111\/j.1365-2710.2005.00670.x.","journal-title":"J Clin Pharm Ther"},{"key":"5006743_CR13","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/11632400-000000000-00000","volume":"29","author":"E Topinkova","year":"2012","unstructured":"Topinkova E, Baeyens JP, Michel JP, Lang PO. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging. 2012;29:477\u2013494. doi:https:\/\/doi.org\/10.2165\/11632400-000000000-00000.","journal-title":"Drugs Aging"},{"key":"5006743_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/gerona\/glr065","volume":"67","author":"RI Lindley","year":"2012","unstructured":"Lindley RI. Drug trials for older people. J Gerontol A Biol Sci Med Sci. 2012;67:152\u2013157. doi:https:\/\/doi.org\/10.1093\/gerona\/glr065.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"5006743_CR15","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/clpt.2011.44","volume":"89","author":"PF Gallagher","year":"2011","unstructured":"Gallagher PF, O\u2019Connor MN, O\u2019Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP\/START criteria. Clin Pharmacol Ther. 2011;89:845\u2013854. doi:https:\/\/doi.org\/10.1038\/clpt.2011.44.","journal-title":"Clin Pharmacol Ther"},{"key":"5006743_CR16","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1046\/j.1532-5415.2002.50607.x","volume":"50","author":"G Onder","year":"2002","unstructured":"Onder G, Pedone C, Landi F, et al. Adverse drug reactions as cause of hospital admissions: results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA). J Am Geriatr Soc. 2002;50:1962\u20131968. doi:https:\/\/doi.org\/10.1046\/j.1532-5415.2002.50607.x.","journal-title":"J Am Geriatr Soc"},{"key":"5006743_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1046\/j.1365-2125.2003.01875.x","volume":"57","author":"PA Routledge","year":"2004","unstructured":"Routledge PA, O\u2019Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 2004;57:121\u2013126. doi:https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01875.x.","journal-title":"Br J Clin Pharmacol"},{"key":"5006743_CR18","first-page":"924","volume":"41","author":"SN Hilmer","year":"2012","unstructured":"Hilmer SN, Gnjidic D, Le Couteur DG. Thinking through the medication list\u2014appropriate prescribing and deprescribing in robust and frail older patients. Aust Fam Physician. 2012;41:924\u2013928.","journal-title":"Aust Fam Physician"},{"key":"5006743_CR19","doi-asserted-by":"publisher","first-page":"e3445","DOI":"10.1136\/bmj.e3445","volume":"344","author":"G Watts","year":"2012","unstructured":"Watts G. Why the exclusion of older people from clinical research must stop. BMJ. 2012;344:e3445. doi:https:\/\/doi.org\/10.1136\/bmj.e3445.","journal-title":"BMJ"},{"key":"5006743_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.maturitas.2011.02.002","volume":"68","author":"CB Carroll","year":"2011","unstructured":"Carroll CB, Zajicek JP. Designing clinical trials in older people. Maturitas. 2011;68:337\u2013341. doi:https:\/\/doi.org\/10.1016\/j.maturitas.2011.02.002.","journal-title":"Maturitas"},{"key":"5006743_CR21","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jacc.2005.06.061","volume":"46","author":"S Laer","year":"2005","unstructured":"Laer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol. 2005;46:1322\u20131330. doi:https:\/\/doi.org\/10.1016\/j.jacc.2005.06.061.","journal-title":"J Am Coll Cardiol"},{"key":"5006743_CR22","doi-asserted-by":"publisher","unstructured":"Nagai N. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation in drug development: regulatory point of view [in Japanese]. Jpn J Pharmacol. 2010;41. doi:https:\/\/doi.org\/10.3999\/jscpt.41.217.","DOI":"10.3999\/jscpt.41.217"},{"key":"5006743_CR23","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1177\/1060028013514376","volume":"48","author":"V Crentsil","year":"2014","unstructured":"Crentsil V, Lee J, Jackson A. Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults. Ann Pharmacother. 2014;48:306\u2013313. doi:https:\/\/doi.org\/10.1177\/1060028013514376.","journal-title":"Ann Pharmacother"},{"key":"5006743_CR24","unstructured":"Ministry of Health, Labour and Welfare. Pharmacovigilance planning (ICH E2E) [in Japanese]. http:\/\/www.pmda.go.jp\/files\/000156059.pdf. Published September 16, 2005. Accessed August 29, 2015."},{"key":"5006743_CR25","unstructured":"Ministry of Health, Labour and Welfare. About the implementation methods of early post-marketing phase vigilance on ethical drugs [in Japanese]. http:\/\/www.pmda.go.jp\/files\/000145855.pdf. Published March 24, 2006. Accessed August 29, 2015."},{"key":"5006743_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1056\/NEJMp1014427","volume":"364","author":"RE Behrman","year":"2011","unstructured":"Behrman RE, Benner JS, Brown JS, et al. Developing the Sentinel System\u2014a national resource for evidence development. N Engl J Med. 2011;364:498\u2013499. doi:https:\/\/doi.org\/10.1056\/NEJMp1014427.","journal-title":"N Engl J Med"},{"key":"5006743_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/pds.2209","volume":"20","author":"KV Blake","year":"2011","unstructured":"Blake KV, Prilla S, Accadebled S, et al. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Pharmacoepidemiol Drug Saf. 2011;20:1021\u20131029. doi:https:\/\/doi.org\/10.1002\/pds.2209.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"5006743_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3820\/jjpe.16.55","volume":"16","author":"Mie IKEDA","year":"2012","unstructured":"Ikeda M, Endo A, Matsui K. The efforts to utilize electronic medical information for safety measures\u2014PMDA\u2019s MIHARI Project [in Japanese]. Jpn J Pharmacol. 2011;16. doi:https:\/\/doi.org\/10.3820\/jjpe.16.55.","journal-title":"Japanese Journal of Pharmacoepidemiology\/Yakuzai ekigaku"},{"key":"5006743_CR29","unstructured":"Pharmaceutical and Medical Devices Agency. MIHARI Project\u2014medical information for risk assessment initiative. https:\/\/www.pmda.go.jp\/english\/safety\/surveillance-analysis\/0001.html. Published 2015. Accessed October 20, 2015."},{"key":"5006743_CR30","unstructured":"European Medicines Agency. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) guide on methodological standards in pharmacoepidemiology (Revision 2). http:\/\/www.encepp.eu\/standards_and_guidances\/documents\/ENCePPGuideofMethStandardsinPE_Rev2.pdf. Published June 18, 2013. Accessed October 20, 2015."},{"key":"5006743_CR31","unstructured":"US Department of Health and Human Services Food and Drug Administration. Guidance for industry and FDA staff best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm243537.pdf. Published May 2013. Accessed October 20, 2015."},{"key":"5006743_CR32","unstructured":"Pharmaceutical and Medical Devices Agency. Guideline for the implementation of pharmacoepidemiology research on the safety evaluation of the drug based on medical information database [in Japanese]. https:\/\/www.pmda.go.jp\/files\/000147250.pdf. Published March 31, 2014. Accessed October 20, 2015."}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479016648731.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2168479016648731","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1177\/2168479016648731\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2168479016648731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479016648731.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T13:00:03Z","timestamp":1598014803000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1177\/2168479016648731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["5006743"],"URL":"https:\/\/doi.org\/10.1177\/2168479016648731","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"18 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}